Trial Profile
A Randomized Phase II Neoadjuvant Study of Sequential Eribulin Followed by FAC/FEC-regimen Compared to Sequential Paclitaxel Followed by FAC/FEC-Regimen in Women With Early Stage Breast Cancer Not Overexpressing HER-2
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Sep 2021
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Paclitaxel (Primary) ; Antiallergics; Cyclophosphamide; Doxorubicin; Epirubicin; Fluorouracil
- Indications Adenocarcinoma; Early breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 28 Dec 2019 Planned End Date changed from 1 Aug 2020 to 31 Aug 2020.
- 28 Dec 2019 Planned primary completion date changed from 1 Aug 2019 to 31 Aug 2020.
- 16 May 2019 Planned End Date changed from 1 Aug 2019 to 1 Aug 2020.